Company Profile
Foresee Pharmaceuticals is biopharmaceutical company in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer.
Its portfolio also includes FP-004 that is in preclinical stage to treat opioids use disorder, FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer, and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline products consist of FP-020 to treat sarcoidosis, idiopathic pulmonary fibrosis, and pulmonary emphysema.
Its portfolio also includes FP-025, a selective matrix metalloproteinase-12 inhibitor, which is in Phase II clinical trial for the treatment of asthma, chronic obstructive pulmonary diseases, and acute respiratory distress syndrome in COVID-19 patients, and FP-045, a selective aldehyde dehydrogenase (ALDH2) activator that completed Phase I clinical study for the treatment of fanconi anemia FP-040, an ALDH2 activator to treat central nervous system diseases. Incorporated in 2013, the company is headquartered in Taipei, Taiwan.